Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.

Antiviral therapy - 1 Jan 2009

Choe Won Hyeok, Hong Sun Pyo, Kim Byung Kook, Ko Soon Young, Jung Young Kul, Kim Ji Hoon, Yeon Jong Eun, Byun Kwan Soo, Kim Kyun-Hwan, Ji Seung Il, Kim Soo-Ok, Lee Chang Hong, Kwon So Young

Abstract excerpt

BACKGROUND: The efficacy of entecavir (ETV) monotherapy in treatment-experienced patients with chronic hepatitis B (CHB) is debatable. METHODS: A total of 22 hepatitis B e antigen (HBeAg)-positive CHB patients who had shown viral breakthrough or suboptimal response with lamivudine (3TC) and adefovir disoproxil (ADV) therapy were treated with 1.0 mg of ETV. Clinical and virological parameters were monitored every...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Multiple, Viral

Share to Guanine

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Lamivudine

Share to Organophosphonates

Source

Identifiers

PMID: 19918102
DOI: 10.3851/IMP1417

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.PMID 19918102Read ↗

Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.Semantic proximity Read ↗

Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.Semantic proximity Read ↗

Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy.Semantic proximity Read ↗

Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.Semantic proximity Read ↗

Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients.Semantic proximity Read ↗

Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.Semantic proximity Read ↗

Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.Semantic proximity Read ↗

Efficacy of Different Nucleoside Analog Rescue Therapies for Entecavir-Resistant Chronic Hepatitis B PatientsSemantic proximity Read ↗

Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.Semantic proximity Read ↗

[Evolution of hepatitis B virus quasispecies during antiviral therapy in one chronic hepatitis B patient].Semantic proximity Read ↗

Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?Semantic proximity Read ↗

Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.